Android app Apple app link

Morgan Stanley Initiates Cidara Therapeutics (CDTX) With a Buy

By Yahoo! Finance   |   1 month ago
Morgan Stanley Initiates Cidara Therapeutics (CDTX) With a Buy

Cidara Therapeutics, Inc. (NASDAQ:CDTX) is a promising growth stock with a Buy rating and $190 price target by analyst Maxwell Skor. The company's lead candidate CD388, an antiviral, shows potential in the influenza prophylaxis market.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.